Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.47 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27319236 | 0.98 | ANPEP (0.48) | ANPEPENPEPRNPEPLTA4HFNTA | |
| SCHEMBL3458066 | 0.98 | ANPEP (0.48) | ANPEPENPEPRNPEPLTA4HFNTA | |
| SCHEMBL1919994 | 0.98 | ANPEP (0.48) | ANPEPENPEPRNPEPLTA4HFNTA | |
| Hydrochloric Acid SCHEMBL2256096 | 0.96 | ANPEP (0.47) | ANPEPENPEPRNPEPLTA4HFNTA | |
| Hydrochloric Acid SCHEMBL2256099 | 0.96 | ANPEP (0.47) | ANPEPENPEPRNPEPLTA4HFNTA | |
| Hydrochloric Acid SCHEMBL1920619 | 0.96 | ANPEP (0.47) | ANPEPENPEPRNPEPLTA4HFNTA | |
| SCHEMBL1920602 | 0.79 | ANPEP (0.42) | ANPEPTP53SLC22A6 | |
| SCHEMBL2254788 | 0.76 | ENPEP (0.47) | ANPEPENPEPRNPEPCA2CA1 | |
| SCHEMBL12360651 | 0.75 | RNPEP (0.38) | ANPEPENPEPRNPEPSLC22A6 | |
| SCHEMBL28370787 | 0.74 | LTA4H (0.35) | LTA4HTP53SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110196014-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | BIOXINESS PHARMACEUTICALS, INC. (CA) | 2011-08-11 | — | — | US | disclosed |
| EP-2326619-A2 | METHIONINE ANALOGS AND METHODS OF USING SAME | Bioxiness Pharmaceuticals, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110196014-A1 | METHIONINE ANALOGS AND METHODS OF USING SAME | MTR, METAP1, AMD1 | ANPEP 476/4885ENPEP 182/4885RNPEP 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.